Title

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.

Authors

Habte Yimer
Jason Melear
Edward Faber
William Bensinger, Myeloma and Transplant Program, Swedish Cancer Institute, Seattle, WA, United StatesFollow
John M Burke
Mohit Narang
Don Stevens
Sriya Gunawardena
Yana Lutska
Keqin Qi
Jon Ukropec
Ming Qi
Thomas S Lin
Robert M Rifkin

Document Type

Article

Publication Date

5-1-2019

Publication Title

British journal of haematology

Keywords

LYRA; bortezomib; cyclophosphamide; daratumumab; multiple myeloma

Abstract

This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4-8 induction cycles of bortezomib 1·5 mg/m

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Recommended Citation

Yimer, Habte; Melear, Jason; Faber, Edward; Bensinger, William; Burke, John M; Narang, Mohit; Stevens, Don; Gunawardena, Sriya; Lutska, Yana; Qi, Keqin; Ukropec, Jon; Qi, Ming; Lin, Thomas S; and Rifkin, Robert M, "Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study." (2019). Articles, Abstracts, and Reports. 1298.
https://digitalcommons.providence.org/publications/1298